Lead Product(s) : APTO-253
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aptose Provides Update on APTO-253 Program
Details : APTO-253 remains an interesting product that has demonstrated MYC repression, which creates optionality across the wider oncology spectrum. Clinical development of the MYC repressor APTO-253 will be discontinued.
Brand Name : APTO-253
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 20, 2021
Lead Product(s) : APTO-253
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting
Details : Early clinical data, along with certain preclinical data, for CG-806, an oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor, and early clinical data for APTO-253, a small molecule MYC inhibitor, will be presented at the 62nd ASH Annual ...
Brand Name : APTO-253
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 04, 2020
LOOKING FOR A SUPPLIER?
Reset All
